DISEASE INDICATIONS: Psoriasis

MANUFACTURER: AbbVie Ltd

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Therapeutic Goods Administration (TGA)

Risankizumab, also known as Skyrizi, is a biologic medication that targets interleukin-23 (IL-23) to treat moderate to severe plaque psoriasis in adult patients.